USANA Health Sciences, Inc.

USANA Health Sciences, Inc. (USNA) Market Cap

USANA Health Sciences, Inc. has a market capitalization of $408.2M.

Price: $22.11

-0.06 (-0.27%)

Market Cap: 408.22M

NYSE · time unavailable

CEO: Kevin G. Guest

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1994-04-04

Website: https://www.usana.com

USANA Health Sciences, Inc. (USNA) - Company Information

Market Cap: 408.22M|Sector: Consumer Defensive

Company Profile

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.

Analyst Sentiment

60%
Buy

From 0 Active Polls

1Y Forecast: $35.00

▲ +58.3% Potential Upside

Consensus Target Metrics

Low Bound

$35

Median

$35

High Bound

$35

Average

$35

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$35.00
▲ +58.30% Upside
Low Target
$35.00
58% Risk
Median Target
$35.00
58% Mid
High Target
$35.00
58% Max
Consensus
Hold
2 / 8 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MApr 4, 2026Jan 3, 2026Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 31, 2024Sep 28, 2024Jun 29, 2024
Market Cap ($M)408311356522576529684723863
Enterprise Value ($M)259162211377425373542359530
Price to Earnings Ratio (P/E)46.7410.30-50.10-19.8114.9714.1739.0116.9320.56
Price/Earnings-to-Growth Ratio (PEG)0.97-8.540.845.83
Price to Sales Ratio (P/S)0.441.241.572.442.442.123.203.614.05
Price to Book Ratio (P/B)0.750.570.670.991.091.001.291.361.68
Price to Free Cash Flow Ratio (P/FCF)137.8643.71-57.52-101.1680.1441.74171.7826.66162.22
Enterprise Value to Sales (EV/Sales)0.650.931.761.801.492.541.792.49
Enterprise Value to EBITDA (EV/EBITDA)3.246.3614.4933.0014.8213.6032.9414.8120.44
Debt to Equity Ratio-1.860.030.030.040.07

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 USANA HEALTH SCIENCES INC (USNA) — Investment Overview

🧩 Business Model Overview

USANA designs and sells branded nutritional and health-related supplement products through a direct-to-consumer model supported by a global network of independent associates/distributors. The value chain centers on (1) product development and sourcing, (2) regulatory-compliant manufacturing and quality controls, (3) distribution through people-driven selling and training, and (4) repeat purchase behavior built around a customer’s routines (supplement regimens) and the continuity of the advisory relationship with their distributor. The model’s economics depend heavily on distributor productivity, customer retention, and the ability to maintain pricing power while controlling promotional intensity.

💰 Revenue Streams & Monetisation Model

USANA’s monetisation is primarily driven by product sales of supplements and wellness formulations. Revenue is typically a blend of:
  • Repeat retail/customer purchasing (recurring in character when customers maintain regimens and subscribe to routine replenishment).
  • Distributor/channel purchasing (which can introduce variability based on inventory replenishment cycles).
  • Programmatic incentives and volume-driven incentives embedded in the distributor compensation structure, which influence order cadence and unit economics.
Margin drivers include: (1) product gross margin supported by sourcing and manufacturing efficiency, (2) marketing and incentive spend efficiency tied to distributor output, and (3) operating leverage from scaling order fulfillment and infrastructure while maintaining compliance and quality costs. Because the company sells branded nutrition products, gross margin resilience depends on maintaining favorable cost structure and avoiding excessive discounting or promotional escalation.

🧠 Competitive Advantages & Market Positioning

USANA operates in a direct-selling branded supplement category where distribution structure and customer routines create meaningful stickiness. Primary moat: Switching Costs + Distribution Network Stickiness (soft moat)
While supplements are not patent-protected in the way pharmaceuticals are, customer behavior can be “sticky” due to:
  • Regimen-based purchasing: customers often continue a multi-product routine, reducing willingness to switch brands without perceived disruption.
  • Relationship-led advisory: the distributor network provides ongoing guidance and product education that makes brand switching less straightforward.
  • Distributor investment in the channel: independent associates invest time and effort in building clientele, creating an internal “stickiness” to the brand’s compensation and training ecosystem.
Competitive benchmarking (direct selling nutrition)
USANA’s closest competitive set includes:
  • Herbalife (HLF): also relies on independent distributors and a broad consumer base in global nutrition and weight management adjacent categories.
  • Nu Skin Enterprises (NUSN): direct-selling model spanning skincare and nutrition/beauty-adjacent wellness products.
  • Amway/Alticor (Amway nutrition brands): large-scale direct selling with broader household penetration and multi-category wellness offerings.
Positioning contrast: These rivals generally compete on distributor reach, product breadth, and incentive plan execution. USANA’s differentiator is its focus on branded nutritional science-oriented formulations paired with a regulated, quality-focused operating model. Competitors with wider category breadth may benefit from cross-category purchasing, but they often face similar challenges in distributor productivity and compliance.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, USANA’s growth potential is tied to TAM expansion in preventive health and nutrition, plus execution in distribution and product credibility.
  • Secular shift toward preventive healthcare: broader consumer adoption of nutrition, immune support, metabolic health, and wellness routines supports continued demand for branded supplements.
  • Global penetration in health-conscious markets: expanding middle-class consumption and rising health awareness can expand addressable customer counts, especially where direct selling remains culturally accessible.
  • Product innovation within allowable regulatory boundaries: iterative formulation improvements and category expansion (within dietary supplement compliance frameworks) can sustain customer engagement and reduce reliance on any single SKU.
  • Channel optimization: improving distributor training, onboarding, and productivity can raise revenue per active distributor while controlling incentives and inventory volatility.
  • Digital augmentation of a people-led model: e-commerce and digital customer journeys can improve reach while preserving the relationship-led purchasing dynamic that underpins repeat demand.

⚠ Risk Factors to Monitor

Key structural and operational risks include:
  • Regulatory and compliance risk: dietary supplement oversight, labeling requirements, and product claim scrutiny can affect product assortments, marketing language, and distribution continuity.
  • Distributor economics and retention risk: direct selling models can experience churn if customer responsiveness weakens or incentives become misaligned with distributor unit economics.
  • Inventory and channel demand variability: distributor ordering can mask end-customer demand, increasing volatility in revenue recognition timing and inventory management.
  • Competitive intensity: larger direct sellers may use scale and category breadth to attract customers; wellness retailers and e-commerce brands can also compete on price and convenience.
  • Quality/supply chain risk: sourcing, manufacturing consistency, and testing outcomes are critical given heightened consumer expectations and regulator focus.

📊 Valuation & Market View

The market typically values direct-selling branded supplement companies on a mix of revenue-based metrics (e.g., P/S) and cash-flow/earnings power (e.g., EV/EBITDA when margin visibility is sufficient). For this sector, valuation sensitivity typically centers on:
  • Revenue durability: whether growth is driven by end-consumer demand versus channel stocking effects.
  • Gross margin sustainability: protection against discounting, input cost pressure, and promotional overhang.
  • Operating leverage: ability to scale fulfillment, compliance, and overhead without disproportionate selling/incentive expense growth.
  • Distributor health indicators: active associate base, retention trends, and revenue per active participant.

🔍 Investment Takeaway

USANA’s long-term case rests on a distribution-centered model that can create customer stickiness through regimen-based repurchasing and distributor relationship continuity. The moat is less about patents and more about soft switching costs and network-driven demand generation. The investment merits strongest when distributor productivity remains stable, end-customer demand is resilient, and compliance and quality systems protect brand integrity while enabling disciplined product innovation.

⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for USNA.

prnewswire.com2026-07-30

New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow

Consumer study reports improvements in brighter-looking, more radiant, andmore even-toned skin after 12 weeks SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- USANA Health Sciences (NYSE: USNA), a global leader in cellular nutrition, today announced the results of a new 12-week consumer study evaluating Glow, USANA's skincare supplement designed to support healthy, radiant-looking skin from within.* The 12-week consumer trial included 36 participants across the United States (22) and Mexico (14).

prnewswire.com2026-07-20

USANA Health Sciences Renews Four-Year Partnership with Nordiq Canada, Deepening Commitment to Clean Sport and Elite Athlete Nutrition

The renewed agreement extends USANA's role as the official nutrition partner of Nordiq Canada, supporting Canada's elite cross-country ski athletes through 2028 and beyond SALT LAKE CITY, July 20, 2026 /PRNewswire/ -- USANA Health Sciences, Inc. (NYSE: USNA), a global leader in science-based nutrition, today announced a renewal of its official partnership with Nordiq Canada, the national governing body for cross-country skiing in Canada. Under the renewed agreement, USANA will continue supplying Nordiq Canada's elite athletes with premium, NSF Certified for Sport® nutritional products designed to support performance, normal muscle recovery after exercise, and long-term health—through the 2030 Olympic Winter Games and beyond.

businesswire.com2026-07-14

USANA Schedules Second Quarter 2026 Earnings Release and Conference Call

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2026 results will be released after the close of market on Tuesday, August 4, 2026. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and insti.

prnewswire.com2026-07-01

Kevin Guest: World Cup Determination Shows the Power of Grit, Preparation, Persistence

SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- As World Cup soccer players push through pressure, fatigue, setbacks and global expectations, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE: USNA), says their pursuit of victory carries a lesson that reaches far beyond the field. It comes down to one of the 12 principles from his book, All the Right Reasons: The Piano Principle.

zacks.com2026-06-30

5 Low P/B Stocks That Investors Can Add to Their Portfolio in July

PAGS, USNA, GM, NEXA and AVT stand out after passing low price-to-book value screens, highlighting five stocks that merit a closer look in July.

zacks.com2026-06-26

Should Value Investors Buy USANA Health Sciences (USNA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com2026-06-25

4 Value Stocks to Buy as Lower Energy Costs Strengthen Market Outlook

Nexa Resources, Avnet, StoneCo and USANA Health stand out as lower oil prices ease inflation worries and boost the case for value stocks.

seekingalpha.com2026-06-18

USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy

USANA Health Sciences is undergoing restructuring, causing temporary margin pressure but positioning for significant future profit expansion. Rise Wellness posted 740% revenue growth, but gross margin fell to 7.1% due to promotional discounts; margin recovery is expected as restocking begins at regular prices. Hiya's revenue dropped 13.3% amid higher CAC from Meta algorithm changes; in-house manufacturing should drive cost savings in H2.

prnewswire.com2026-06-16

USANA Celebrates 10 Years of Making the World a Better Place During World Service Week

SALT LAKE CITY, June 16, 2026 /PRNewswire/ -- For the past 10 years, the USANA community comes together every June through acts of service during World Service Week led by the USANA Foundation. World Service Week unites the USANA family across continents for a week of service and compassion.

zacks.com2026-06-12

5 Low Price-to-Book Stocks That Are Worth Buying in June

STNE, USNA, STRA, NEXA and CVS passed a low price-to-book screen, combining discounted valuations with projected long-term EPS growth.

zacks.com2026-06-11

These 4 Low Price-to-Cash Flow Stocks Have Winning Potential

Nexa Resources leads a screen of four low P/CF value stocks, with consensus sales and EPS growth forecasts and wildly mixed 12-month returns.

zacks.com2026-06-10

Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

prnewswire.com2026-06-04

USANA Earns Dual Best of State Honors for Product Innovation and Development

USANA's CellSentials and Research and Development team honored at the awards SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- USANA, a leader in global nutrition, earned two Best of State awards in Salt Lake City, Utah, recognizing its CellSentials supplements and Research and Development team. USANA took home two Best of State medals this year in the following categories: Dietary Supplement—USANA CellSentials took home this honor for the tenth consecutive year  Research and Development—USANA's R&D team won for the eighth time To learn more about USANA and its award-winning products, please visit USANA.com.

prnewswire.com2026-06-01

Kevin Guest Encourages Professionals to Prioritize Wellness During Professional Wellness Month

USANA CEO says small daily habits can strengthen health,  improve workplace culture, and help others thrive SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- As Professional Wellness Month begins in June, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE: USNA), is encouraging professionals, leaders, and organizations to make wellness a priority both at work and at home. He says healthier habits create stronger people, stronger teams, and stronger communities.

zacks.com2026-05-25

Should Value Investors Buy USANA Health Sciences (USNA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-04

"USNA reported Q1’26 revenue of $250.2M and EPS of $0.41, with net income of $7.5M (net margin ~3.0%). QoQ, revenue rose from $226.2M (Q4’25) to $250.2M (+10.7%) while net income improved from -$1.8M to +$7.5M (turnaround). YoY, revenue edged down from $249.5M (Q1’25) to $250.2M (+0.3%), but profitability strengthened: net income moved from $9.4M (Q1’25) to $7.5M (−20.2%). Over the last four quarters, gross margin has softened slightly versus earlier quarters (~75.6–78.2% range; Q1’26 at ~76.2%), while operating margin recovered in Q1’26 to ~5.5% from a negative net quarter in Q3’25/Q4’25, indicating improved cost control. Cash flow quality looks solid: operating cash flow was $9.8M in Q1’26 and free cash flow was $7.1M, versus negative operating cash flow in Q3’25 and Q4’25. The balance sheet remains resilient with substantial liquidity ($162.8M cash) and low leverage (short-term debt $14M; net debt about -$148.8M). Shareholder returns: market price is $20.06 with 1-year performance of -14.4% and no dividend/buybacks reported in this dataset, implying total shareholder return has been primarily driven by price (negative) rather than yield."

Revenue Growth

Neutral

QoQ revenue +10.7% ($226.2M to $250.2M); YoY revenue +0.3% ($249.5M to $250.2M), indicating flat growth.

Profitability

Neutral

Net income turned from -$1.8M (Q4’25) to +$7.5M (+$9.3M QoQ). YoY net income declined ~20.2% (from $9.4M). Net margin improved QoQ (negative to ~3.0%).

Cash Flow Quality

Positive

Q1’26 operating cash flow $9.8M and free cash flow $7.1M were positive. Prior quarters (Q3/Q4’25) were negative, suggesting improving cash generation; no dividends reported.

Leverage & Balance Sheet

Good

High liquidity ($162.8M cash) with very low leverage (debt $14M). Net debt is deeply negative (~-$148.8M). Equity remains strong (~$595M total equity).

Shareholder Returns

Neutral

1-year price change is -14.4% (weak). No dividend yield and no buybacks/dividends reported in cash flow for Q1’26, so total shareholder return has likely underperformed.

Analyst Sentiment & Valuation

Caution

Consensus target of $35 vs. current $20.06 implies upside, but valuation multiples (e.g., P/E ~10.3) appear not distressed; sentiment looks cautiously positive.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

USNA’s Q1 2026 shows an accelerating omni-channel mix with continued stabilization in core nutritional despite expense pressure. Core nutrition net sales were $204M, up 7% sequentially, attributed to active customer growth in China around Lunar New Year. HYA contributed $32M and 186k active monthly subscribers; however, HYA SG&A rose year-over-year and sequentially due to Meta advertising disruptions increasing customer acquisition costs, plus incremental operational burden from new market entry (Canada, UK) and retail rollout at Target. Rise Wellness delivered $14M net sales, >8x prior-year Q1 and +143% sequentially, powered by Costco’s Protein Pop Plus national launch and supported by weekly reorder placements. Management reaffirmed FY2026 consolidated net sales of $925M–$1.0B and HYA $140M–$155M. Operationally, technology modernization is progressing with incremental funding, and HYA in-house manufacturing/packaging should begin driving incremental margin efficiencies in 2026. Main risk remains continued Meta-driven acquisition cost volatility and early-stage retail ramp variability.

AI IconGrowth Catalysts

  • Core nutritional: sequential improvement with active customer growth in China around Lunar New Year customer acquisition activity
  • Core nutritional: rollout of enhanced brand partner compensation plan to improve distributor productivity/retention
  • Omni-channel HYA: expansion to new markets and channels (Canada launch in January; UK launch in March; retail entry at Target; added Amazon diversification)
  • Omni-channel Rise Wellness: Costco-driven momentum from national launch of Protein Pop Plus; retail expansion momentum (Target end caps; Walmart presence already at ~500 stores)
  • Cost/margin lever: in-house manufacturing and packaging for HYA beginning incremental margin efficiencies in 2026 after recent platform changes (ERP, 3PL transition)

Business Development

  • HYA: retail partner Target (products available; end caps placed about a week after going live; Canada/UK market expansion)
  • HYA: Meta advertising environment disruptions beginning in 2025 driving higher customer acquisition costs
  • Rise Wellness: Costco relationship with ongoing sell-through and weekly reorder placements; conversations on new Protein Pop product types
  • Rise Wellness: agreements with nine additional major U.S. retailers for 2026 expansion (timing split across Q2 and Q3)
  • Rise Wellness: Walmart penetration at ~500 stores; expectation to expand further within the U.S.
  • HYA manufacturing shift: brought manufacturing/packaging in-house post acquisition (with ERP modernization and 3PL transition)

AI IconFinancial Highlights

  • Core nutritional: net sales $204M grew 7% sequentially (driven by active customer growth, especially China around Lunar New Year)
  • HYA: $32M net sales; active monthly subscribers 186k (modest sequential improvement from Q4)
  • Rise Wellness: $14M net sales, >8x prior-year Q1 and +143% sequential increase
  • Omni-channel: omni-channel net sales expected to be >20% of total net sales in 2026 (vs 16% in 2025 and ~1% two years ago)
  • SG&A: for HYA, SG&A higher sequentially and vs prior year; attributed to operational resource consumption from retail entry and UK/Canada expansion plus elevated short-term customer acquisition costs from Meta algorithm/disruptions
  • Guidance (reaffirmed): consolidated FY2026 net sales $925M to $1.0B
  • HYA FY2026 guidance reaffirmed: net sales $140M to $155M

AI IconCapital Funding

  • Balance sheet usage: used a lot of cash building Costco inventory; still selling through and reorders continue on a weekly basis
  • No explicit buyback authorization/amounts, debt levels, or cash runway figures stated in the transcript

AI IconStrategy & Ops

  • Technology modernization: incremental but modest investment in 2026 funded mainly via repurposing existing resources and operational efficiency savings
  • Core systems modernization: new ERP implemented; 3PL transition completed; objective to improve customer experience and drive IT cost efficiencies
  • Supply chain/margin: HYA manufacturing and packaging moved in-house; incremental margin efficiencies expected to begin in 2026
  • HYA operating focus: diversify advertising/consumer spend to reduce reliance on any single advertising method and improve insulation from Meta environment volatility
  • Rise/WP planning: operations team managing inventory and demand planning across Rise and Protein Pop to create efficiencies

AI IconMarket Outlook

  • Macro (China): management stated China macro environment is stable relative to the rest of the globe; no material impact observed as of yet from potential Iran/fuel-price spillover ("too early to tell")
  • HYA channel build: Target placement is early (about two-plus weeks on shelf; end caps placed about a week prior); management expects a better read over the next few weeks and kept guidance in place
  • Rise growth trajectory: Protein Pop to expand with nine additional retailers (some in Q2, some in Q3); Target cadence described as consistent since Aug/Sep

AI IconRisks & Headwinds

  • HYA profitability/expense pressure: higher short-term customer acquisition costs due to disruptions in the Meta advertising environment (beginning 2025), contributing to higher SG&A
  • Omni-channel channel ramp uncertainty: retail performance, especially UK and Target, described as early-stage/"build as we go" with expectations of learning and improvement over coming weeks/months
  • Cost timing: cash usage tied to building Costco inventory (working-capital intensity) even though sell-through is ongoing
  • Retail execution risk: Costco iteration/ordering variability (discount agreed upfront to drive sell-through; management indicated long-term cadence not fully known)

Q&A: Analyst Interest

  • China macro & fuel-price sensitivity: Management said China macro is comparatively stable and “insulated” from broader inflation pressures. On Iran/fuel-price effects, they stated it’s “too early to tell,” and current feedback from brand partners/China leadership shows no material impact yet.
  • HYA SG&A drivers & channel rollout effects: Management linked higher HYA SG&A to retail diversification resource consumption (retail push late in quarter plus Canada/UK entry) and Meta advertising algorithm disruptions causing higher short-term customer acquisition costs versus year-ago comparisons.
  • Rise/Protein Pop retailer momentum: Management confirmed weekly reorder placements from Costco tied to ongoing sell-through; earlier cash outlay supported building Costco inventory. They said Target cadence is consistent since Aug/Sep, and cited agreements with nine additional major U.S. retailers (Q2/Q3 timing) plus ~500 Walmart stores to expand further.

Sentiment: MIXED

Note: This summary was synthesized by AI from the USNA Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for USNA.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (USNA)

© 2026 Stock Market Info — USANA Health Sciences, Inc. (USNA) Financial Profile